#USA #Cambridge #Hemab Therapeutics #HMB-002 #Sutacimig

Hemab Therapeutics Secures $157 Million Series C Financing

Cambridge, MA and Copenhagen, Denmark - Hemab Therapeutics, a biotechnology company focused on developing innovative prophylactic therapies for uncommon but severe bleeding disorders, has announced the successful completion of a $157 million Series C funding round. This financing was significantly oversubscribed and led by prominent life science investors, including Sofinnova Partners and additional participation from major global asset management firms and sovereign wealth funds, indicating strong confidence in Hemab’s mission to pioneer treatment options for patients with high unmet medical needs.

Breakthrough Innovations in Hemophilia Care

The primary goals of this funding include advancing the development of Sutacimig, which is poised to become the first preventive treatment for Glanzmann thrombasthenia (GT), a serious bleeding disorder. Recently completing its Phase 2 trials, Sutacimig is set to move into registration studies in 2026, reflecting promising progress. For families like that of Alexandra Sullivan, who has two sons with GT, the urgency for effective treatments cannot be overstated. “A simple fall can lead to life-threatening situations for my boys,” she shares, emphasizing the need for safe and effective options that could instill a sense of normalcy in their lives.

Advancing Treatments for Von Willebrand Disease

Furthermore, this funding round will bolster efforts to advance HMB-002, an innovative antibody-based therapy targeting Von Willebrand Disease (VWD). This condition, characterized by deficiencies in Von Willebrand Factor, often leads to excessive bleeding, and the treatment's Phase 1 trials have shown it addresses the disorder’s root causes, potentially altering the landscape of treatment options available. Jeanette Cesta, Executive Director of the VWD Connect Foundation, highlighted, “For too long, patients have watched hemophilia treatments evolve while we remain in the shadows.”

Patients at the Heart of Development

Hemab's strategy has been shaped by deep patient engagement and groundbreaking research initiatives, including studies that explore the natural history of both GT and VWD. These efforts have unveiled the substantial impact of these conditions on patients' quality of life, influencing Hemab’s commitment to developing therapies that go beyond merely treating symptoms.

Expanding the Clinical Pipeline

The new financial resources will enable Hemab to broaden its clinical pipeline, with preparations for another new drug candidate, HMB-003, to be announced in early 2026. The company’s overarching goal is to build a comprehensive treatment strategy addressing the considerable medical needs surrounding severe bleeding disorders. “Investments like this validate our approach to building the ultimate clotting company,” stated Benny Sorensen, MD, PhD, Hemab's CEO. The support from innovative investors reassures the team's ability to advance their promising pipeline.

Conclusion

The successful funding round positions Hemab to make significant strides in the therapeutic landscape for bleeding disorders, driven by a commitment to innovative science and patient-centered care. As Hemab pioneers these revolutionary treatments, the impact on the lives of patients with these conditions could be life-changing, ushering in a new era of hope and improved health outcomes. Stay tuned for more updates as Hemab transforms the landscape of hemophilia care and continues to push forward with their cutting-edge therapies.

For more on Hemab Therapeutics and their groundbreaking initiatives, visit hemab.com or follow them on social media to keep up with their progress in developing crucial therapies for underserved patients.